Objective: Characterize failure and resistance above and below guidelinesrecommended 1000 copies/ml virologic threshold, upon second-line failure.
HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya [1] . Access and eligibility to antiretroviral therapy (ART) are increasing globally; however, only 46% of ART-eligible individuals receive it, a vast treatment gap [2, 3] . Treatment failure in RLS upon nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART is estimated at 24% within 12 months and 33% within 24 months [4] ; and upon protease inhibitor-based second-line ART at 23% within 12 months and 26% within 24 months [5] . As the treatment gap narrows, more individuals in settings where routine sustainable virological monitoring capacity and third-line salvage regimens are limited will fail therapy with potential rises in transmitted and acquired drug resistance [3, 6] . This concerning scenario, which may result in poor clinical outcomes, mandates strategic planning to minimize resistance evolution and transmission [7, 8] .
Adult HIV prevalence in Kenya (5.6-6.1%; 2012) is the 12th highest worldwide, representing a high health burden [9, 10] of an epidemic with multiple circulating subtypes [11] . ART access has significantly increased in Kenya since 2001, with positive clinical outcomes [1, 12] . As of June 2017, 70% of eligible adults were receiving ART, 93% on first-line (www.nascop.or.ke). Standard first-line regimens included zidovudine (ZDV) or stavudine (d4T); lamivudine (3TC); and nevirapine (NVP) or efavirenz (EFV), with tenofovir (TDF) substituting d4T in 2013, per WHO guidelines [3] . Data on transmitted [11, [13] [14] [15] [16] and first-line [17] [18] [19] [20] [21] resistance are limited, and nonexistent for second-line, which mostly includes ZDV or TDF, 3TC, and lopinavir/ritonavir (LPV/r) [22] , with atazanavir available since 2014.
At the Academic Model Providing Access to Healthcare (AMPATH), a large HIV program in sub-Saharan Africa [23] , patients are suspected to fail ART with two consecutive viral load tests more than 1000 copies/ml, despite adherence counseling. Patients failing first-line are switched to second-line, the use of which has consistently increased, with 3943 patients receiving it in 2010, and 6968 in 2016. Third-line options (e.g. darunavir, etravirine, raltegravir) have been available since 2015, with a recent addition of dolutegravir; however, this process is still restricted, and data on the extent and impact of resistance upon continued second-line, particularly at viral load below the WHO-defined failure threshold of 1000 copies/ml [3] , are limited [24] .
To address the lack of data on failure and resistance in experienced individuals failing second-line in Kenya and other RLS, we determined the prevalence and correlates of second-line virologic failure in a large AMPATH adult cohort, examined resistance patterns among those with detectable viral load above and below 1000 copies/ml, and ascertained their accumulation and longitudinal effect on future drug options. We hypothesized substantial resistance accumulation over time with impact on thirdline salvage regimen options at both high-level and lowlevel viremia (LLV). AMPATH patients are managed with an electronic medical record [25] according to locally developed protocols per WHO guidelines. At the time of the study CD4 þ s were done at HIV diagnosis and every 6 months, and viral load access was limited. Individuals suspected as failing first-line by consecutive viral load more than 1000 copies/ml or immunological failure were switched to a standard second-line regimen. Individuals failing second-line remained on this regimen for lack of thirdline options.
Methods

Study setting
Participant enrollment
Inclusion criteria were: HIV-positive; at least 18 years; on at least 24 weeks LPV/r-based second-line; at least 6 months prior first-line (ZDV/d4Tþ3TCþNVP/EFV); and more than 50% self-reported adherence in the prior month and 7 days. Between June 2011 and May 2012, participants meeting inclusion criteria were offered enrollment, consenting participants were enrolled sequentially and interviewed, charts were reviewed for demographic, clinical and laboratory characteristics, and blood samples were obtained for CD4
þ , viral load and pol genotyping. Participants with detectable viral load (>40 copies/ml) at enrollment (first visit) were invited for a second visit 1 month later for repeat pol genotyping, after verification of unchanged ART and adherence. Lifespan and Moi University ethics committees approved the study.
Laboratory methods
CD4
þ (FACSCaliber system; Becton Dickenson, San Jose, California, USA) and HIV viral load (Amplicor, Version 1.5; Roche Molecular, Pleasanton, California, USA) testing was done at the AMPATH laboratory, where they are routinely performed for clinical and research purposes. Plasma samples from both visits were frozen (À80 8C), batched and shipped to the Kantor lab for pol genotyping, as described [21] . Briefly, viral RNA was extracted from 400 to 1000 ml plasma via Biomerieux's MiniMAG (Durham, North Carolina, USA), followed by reverse transcription and PCR using SuperScript III First-Strand Synthesis System and Platinum Taq DNA Polymerase High Fidelity (ThermoFisher Scientific, Waltham, Massachusetts, USA). A 1.3 kb fragment spanning the pol gene (2147-3503, HXB2) was Sanger-sequenced and assembled with Sequencher v4.10.1.
Statistical analysis
Demographic and clinical data included age, sex, ART history including prevention of mother-to-child transmission (pMTCT) and treatment interruptions, prior pregnancy, tuberculosis (TB) treatment and previous CD4 þ s and viral loads. Sequence quality control was performed with SQUAT [26] . Resistance interpretation and predicted susceptibilities were evaluated using Stanford Database tools [27] . Measures of resistance at visits 1 and 2 included number of mutations and number and type of drug classes with associated resistance. Patients were classified as having resistance to current regimens if at least one medication had low-level or higher predicted resistance; and to future regimens if they had low-level or higher predicted resistance to at least one future medication (etravirine, rilpivirine, tenofovir, didanosine, abacavir, atazanavir, darunavir). Counts of resistance to future medications omitted currently prescribed drugs; counts of susceptibility to future medications included current drugs if susceptible. Accumulated resistance was defined as new mutations, seen in the second but not first visit. Visit 2 susceptibility was taken as the worse of the two visits. Pol subtyping was derived with REGA [28] . Viral load groups, based on visit 1 viral load, were defined as 'Undetectable' -viral load below lower limit of detection ( 40 copies/ml); 'LLV' -detectable viral load 1000 copies/ml or less; and 'Failure' -viral load more than 1000 copies/ml. We assessed relationships between viral load group and age, sex, WHO stage, TB treatment, time on first-line, time on second-line, adherence, CD4 þ , treatment interruptions, unique regimens (nontraditional first-line/second-line), number of first-line/ second-line regimens, previous pregnancies, pMTCT treatment, and subtype using unadjusted logistic regression. One multivariable logistic regression was fit for each comparison using the covariates found to be most highly correlated with viral load group. Odds ratios (ORs) compare failure vs. nonfailure, detectable vs. undetectable, and failure vs. LLV. To examine representativeness of genotype data, demographic and clinical measures for those with and without genotypes were compared using Fisher Exact and Wilcoxon Rank Sum tests, stratified by viral load group.
Multiple statistical methods were used to examine associations between failure group (LLV vs. failure) at visit 1 as the predictor and various resistance measures as outcomes. At visit 1, dichotomous resistance mutation outcomes (e.g. any resistance) were examined using unadjusted logistic regression; categorical measures (e.g. resistance category) using Fisher Exact tests; and mutation counts using unadjusted Poisson regression. Tests for mutation outcomes at visit 2 were adjusted for the value of the measure at visit 1. At both visits, current and future medications (finite quantitative measures) were compared using t tests. 95% confidence intervals that exclude the value of the null hypothesis (i.e. 0 for t-tests and 1 for logistic and Poisson regression) were considered statistically significantly different.
Results
Study population
A total of 394 eligible participants were enrolled (Table 1) , lower than the planned 438 because of slow enrollment. The median age at enrollment was 42 years (IQR 35-48), 60% were women, and 70% had WHO stages 3 and 4. Before enrollment, participants were on second-line for median 1.9 years (IQR 0.8-4.1). Most common regimens included LPV/r with abacavir and didanosine with or without lamivudine (52%), LPV/r with ZDV or abacavir with didanosine with or without lamivudine (23%) and LPV/r with tenofovir and lamivudine with or without abacavir (19%; other regimens 1%). Median time on first-line was 2.9 years (IQR 1.9-4.1), most commonly lamivudine, zidovudine/stavudine and nevirapine (78%). Twenty-four percent were exposed to several second-line regimens and 39% to several first-line regimens. Treatment interruption on second-line was experienced by 3% (median 47 days, IQR , 4% between first-line/second-line (median 69 days, IQR 32-125), and 11% on first-line (median 49 days, IQR 28-70). Most participants reported complete adherence in the prior month (97%) and 7 days (94%). Eight percent received anti-TB medications on second-line. Among women, 38% had previous pregnancies, 70% once, and 16% received pMTCT ART. Median CD4 þ cell counts were 282 cells/ml (IQR 182-419) and 17% (IQR 12-23), 28% with AIDS-defining CD4 þ cell count less than 200 cells/ml.
Virologic treatment failure
Detectable viral load was seen in 48% (n ¼ 191; median 521 copies/ml, IQR 116-3,876), and 21% had viral failure (viral load >1000 copies/ml; n ¼ 82; median 5424 copies/ml, IQR 1826-93 660; Table 1 ). Higher likelihood of viral load more than 1000 copies/ml vs. 1000 copies/ml or less was associated with younger age, concurrent TB treatment, shorter time on second-line, lower CD4
þ cell count and percentage, and longer treatment interruption while on first-line, with similar results in the univariable and multivariable analyses for age, concurrent TB treatment, time on second-line and CD4 þ count. Among women, prior pregnancy was significantly associated with viral load more than 1000 copies/ml (Supplementary Table 1 , http:// links.lww.com/QAD/B346).
Participants with detectable viral load were similar to those with undetectable viral load on most variables, except less time on second-line in univariable analysis and lower CD4 þ values in both analyses. In univariable analysis, compared with participants with LLV, those with viral failure were younger, less likely with complete 1-week adherence, and had lower CD4 þ values. CD4 þ cell count remained significant in the multivariable model. Among women, those with failure were more likely to have ever been pregnant, but if pregnant, less likely to have taken ART for pMTCT (Supplementary Table 1 , http://links.lww.com/QAD/B346).
Drug resistance and diversity
Pol sequences were available for 105 of 191 (55%) participants with detectable viral load, 35 of 109 (32%) with viral load 1000 copies/ml or less and 70 of 82 (85%) with viral load more than 1000 copies/ml. Clinical and demographic characteristics of participants with/without genotypes did not differ, other than association with increased viral load in participants with available genotypes (Supplementary Tables 2 and 3 , http:// links.lww.com/QAD/B346).
Seventy-nine percent of participants with genotypes had at least one resistance mutation; 67% NRTIs, 74% NNRTIs, 9% PIs, 57% dual-class, and 7% triple-class resistance. Figure 1 demonstrates resistance prevalence by viral load threshold, drug class category and subtype. Of genotyped viruses, 58% were subtype A, 22% subtype D, 8% subtype C and 12% others (4% subtype G, 2% subtype AC, 6% subtype AD, 1% subtype DC). The most prevalent (>20%) RT mutations included NRTIassociated M184V, T215Y/F/N/V, D67N/G, M41L and K219Q/R/N/E; and NNRTI-associated K103N/S, Y181C/V and G190A/S. The two most common protease inhibitor-associated mutations were M46L/I and V82A/L (Supplementary Figure 1 , http:// links.lww.com/QAD/B346). Higher viral load was associated with having fewer mutations (rate ratio 0.84 per 1-log 10 higher viral load, CI ¼ 0.74-0.97, P < 0.05). At the second visit, those with LLV were on average resistant to 1.65 medications in their current regimen compared with 1.00 medication among those with viral load more than 1000 copies/ml (P ¼ 0.049, Table 2 ). Additionally, those with LLV were susceptible to fewer of the medications in their current regimen at visit 1 and 2 (P ¼ 0.053). Those with LLV were susceptible to fewer future medications at visit 1 (CI ¼ À1.81 to À0.11, P < 0.028) and visit 2 (CI ¼ À2.23 to 0.2, P ¼ 0.100) than those with viral load more than 1000 copies/ml. Older participants were at increased risk of accumulating mutations (OR 2.35 per 10 years older, CI ¼ 1.06-5.20, P < 0.05), whereas women were at decreased risk (OR 0.2, CI ¼ 0.05-0.84, P < 0.05, data not shown). There was a nonsignificant trend towards increased risk of accumulation in participants with higher CD4 þ cell counts (OR 1.65 per 100 cells higher, CI ¼ 0.99-2.77, P ¼ 0.064). Resistance accumulation occurred in 36% (10/28) of participants with subtype A, 25% (1/4) subtype C, 54% (7/13) subtype D, and 33% (1/3) other subtypes (P > 0.05).
Predicted susceptibilities to future options
At enrollment, 46% (48/105) of genotyped participants, in both viral load categories, had predicted intermediate-high level resistance to at least one future drug option: 26% etravirine, 29% rilpivirine, 18% tenofovir, 30% didanosine, 31% abacavir, 6% atazanavir, and 1% darunavir. Of the 48 patients with two available genotypes, 21% (10/48) had increased levels of predicted resistance at the second visit to intermediate-high levels, to at least one future drug option: 4% etravirine, 4% rilpivirine, 10% tenofovir, 13% didanosine, 15% abacavir and 2% atazanavir, more pronounced at LLV (Fig. 2) .
Discussion
The goal of this study, the first of its kind in Kenya, was to guide management of HIV-infected persons failing second-line ART. In an analysis of 394 adults on second-line, 48% had detectable viral load and 21% had viral load more than 1000 copies/ml. Participants had low-level (9%) protease inhibitor resistance, but extensive NRTI (67%), NNRTI (74%) and dual/triple-class (64%) resistance, at viral load levels above and below the WHO threshold of 1000 copies/ml. Moreover, 40% of participants with follow-up sequences after an average 59 days accumulated resistance mutations, even at low-level viral loads, compromising potential future treatment options.
To our knowledge, this is the first report of resistance development at LLV in RLS. Almost one-third of participants in this study had LLV, consistent with current literature [29] . Although we and others identified correlates of persistent LLV, these vary widely and no specific risk factors have been identified and broadly accepted [29] . In RLS, resistance mutations at LLV upon second-line failure have not yet been investigated, mostly as individuals at this viral load range are not considered as failing ART per current WHO guidelines and their genotyping is more challenging. LLV studies in developed settings report resistance in 17-72%, suggesting detrimental outcomes of allowing patients to remain on therapy with low-level viral replication [24, 30, 31] . Participants with LLV in our study had 79% resistance and 72% dual-class resistance, higher than reported in non-RLS, with an even significantly higher prevalence of NRTI mutations compared with participants with viral load more than 1000 copies/ml. This is concerning, since these individuals are not considered as failing ART in most RLS, even with the now recommended annual viral load monitoring [10, 32] . The 42% of participants with LLV who demonstrated resistance mutation accumulation further emphasize the potential impact of replication at this level. Additional investigation is needed to examine the impact of LLV resistance and the need to consider lowering the viral load threshold definition for ART failure and the sensitivity requirements for drug resistance testing assays.
In this study, the first to longitudinally examine intrapatient resistance accumulation upon second-line failure in RLS, 40% of participants accumulated mutations. A prior study in Nigeria demonstrated a similar concept, but using cross-sectional data [33] . Despite low overall protease inhibitor resistance, two participants accumulated new protease inhibitor mutations in the short time period between study visits. Accumulation of protease inhibitor mutations can lead to darunavir resistance [34] , and indeed four patients (4%) in our cohort were found to have some resistance to darunavir, and one (1%) had intermediate resistance to this third-line drug.
Second-line failure and resistance in Kenya Kantor et al. 2491 Interestingly, most participants who accumulated resistance had new NNRTI mutations in the second visit, despite not being on this ART class as part of second-line. This may be explained, though not examined here, by selection of more fit viral quasispecies with linked NNRTI mutations on the same viral genome [35] , and the low-impact NNRTI mutations may have on viral fitness [36] . The distinction between mutation accumulation and re-emergence must, therefore, be further examined.
Virological failure rates of second-line ART in RLS vary widely (5-72%) across studies, settings and methodologies [5, [37] [38] [39] [5, 38, 39] , longer time on first-line [5] and shorter time on second-line ART [39] , lower CD4 þ cell counts and higher viral load at second-line initiation [39, 40] , being women [41] and delayed switch to second-line [41] . We confirm some of these observations and extend them with other correlations of second-line failure: First, longer treatment interruptions while on first-line, consistent with reports of its association with first-line failure, poor adherence and/or resistance mutation accumulation [21, 42] . Second, concurrent TB treatment, possibly resulting from medication interactions, particularly rifampicin and its induction of the CYP 450 enzymes, and the ensuing lower protease inhibitor concentrations [43] . This is an important finding in light of the high TB prevalence in RLS, which was previously shown in children [44] , and recently in South-African adults [45] . Third, prior pregnancies among women, and if pregnant, less pMTCT exposure, possibly related to low-engagement in care. The finding that younger age is associated with second-line failure, contrasts prior reports [39, 40] and may be related to specific settings. Altogether, these highly variable findings point to potential interventions to improve treatment monitoring and sustain secondline ART.
The low (9%) protease inhibitor resistance upon secondline failure is consistent with reports from RLS, ranging from 6 to 25% [34, 38, [46] [47] [48] , as well as earlier reports, mostly from developed countries, with a slightly wider (0-33%), though still low, range [49] [50] [51] [52] [53] [54] . As expected, considering future ART options, almost all participants with LPV/r resistance were also resistant to atazanavir, and darunavir seems an appropriate third-line option, as suggested by current Kenya ART guidelines [10] . The implications of low-protease inhibitor resistance upon second-line failure on subsequent ART susceptibilities and ability to recycle protease inhibitors, and the impact of postulated causes to such low resistance, including adherence [48, 55] , minority resistance variants [56] , and newer resistance mechanisms [57] [58] [59] , are under investigation. Higher rates (63-87%) of protease inhibitor resistance have been reported from India, Vietnam and Nigeria [33, 37, 60] ; and reasons for this discordance, possibly associated with past ART exposure, differential treatment monitoring, viral subtype and host factors, should be further examined. The high reverse transcriptase resistance (65-95%) found here was associated with almost 30% predicted resistance to rilpivirine and etravirine, the newer-generation NNRTIs being considered in third-line regimens [10] . This augments similar reports from India (29%) [37] , Mali (38%) [46] , and Nigeria (at least 26%, based on mutational analysis of published genotypes) [33] . Though high, these data indicate that some patients may still be susceptible to these medications, if genotyping was available in this setting. Importantly, following the report of the first case of a multidrug resistant isolate in sub-Saharan Africa [61] , two patients in this study had intermediate-high-level resistance to all first-line/second-line drugs available in the public sector (3TC, FTC, TDF, ABC, DDI, ZDV, d4T, EFV, NVP, ATV and LPV), substantiating and supporting the strategic need for third-line ART in RLS [10, 62, 63] .
HIV-1 subtype may be relevant to clinical care and to resistance development [64] [65] [66] [67] . Few studies have assessed second-line resistance in non-B subtypes [33, 37, 46, 47] . Grossman et al. found no significant differences in second-line resistance development between subtypes B and C [52] , and other studies have not included enough subtype diversity to allow intersubtype comparisons. In this study, allowing resistance evaluation upon second-line failure in a RLS with diverse circulating subtypes, we found that at viral load greater than 1000 copies/ml, subtype D viruses had significantly less resistance compared with subtype A. These findings contrast data from Uganda demonstrating more resistance in subtype D vs. subtype A, though not solely upon second-line failure [68] . A larger study assessing differences in second-line failure and resistance between subtypes could elucidate the cause of such findings, and help guide clinical care in areas with diverse subtypes.
The major limitations of the present study are primarily its cross-sectional nature and the lack of continuous virologic monitoring and confirmed testing for viral load failure, limiting the ability to rule out viral blips, estimate time to virologic failure and determine duration of time on a failing regimen. This study design, however, allowed for accrual of a large number of patients, and unfortunately the limited monitoring is representative of routine circumstances in many RLS, even today [69] . Additionally, adherence was based on self-report; pre-ART and pre-second-line resistance testing were not available; and resistance testing sensitivity was limited to conventional, population-based pol genotyping, with no consideration of gag/env mutations or effects of minority variants. Lastly, treatment and monitoring guidelines evolve rapidly and new and improved ART as well as more routine viral load testing are available in some RLS, different than the study's settings. However, concepts presented here hold across guidelines and treatments, and will still be relevant in many settings for years to come.
In conclusion, in this large study in Kenyans on secondline ART, we found high rates of failure, extensive overall but low protease inhibitor resistance and resistance accumulation at viral load levels above and below the WHO treatment-failure threshold, that impact treatment options. Considering increased global ART access, the aging HIV-infected population and existing cost constraints in RLS, optimization of adherence and treatment monitoring (e.g. viral load/resistance testing) are required to support current local and global HIV cascade goals [70] [71] [72] . Continued investigation into resistance mechanisms, in particular when protease inhibitor resistance is absent and good adherence is documented, is needed to improve resistance detection and ART strategies [73] . As in resource-rich settings, treatment goals in RLS should be geared towards achieving virologic suppression in ART-experienced patients with resistance, making ART available to all and strategically planning for thirdline regimens.
